Genetic causes of hypertension identified

March 18, 2002

(Washington, DC)-- Researchers at the University of Virginia and Georgetown University have identified three abnormalities in a single gene that are linked to hypertension. Possessing any of these genetic variations increases the likelihood of developing essential hypertension, the most common class of high blood pressure. Their study, the result of an 18-year UVa-Georgetown research collaboration, appears in the March 19 issue of the Proceedings of the National Academy of Sciences.

Essential hypertension affects 25% of adults and constitutes a major risk factor for stroke, heart attack, heart failure, and kidney failure. About 50% percent of essential hypertension is thought to be hereditary. Determining the genetic cause of essential hypertension has been difficult because the level of blood pressure is the result of the interplay between heredity and environment. Diagnosis and early treatment of hypertension are important because hypertension-related diseases are the leading causes of morbidity and mortality in industrialized countries.

The researchers report that these gene variations, also called polymorphisms, either by themselves or through interaction with variations of other genes, are associated with hypertension in several populations: Caucasian American, Ghanaian, and Japanese. The presence of these gene variations can be determined by a simple genetic test developed by the researchers. This test assesses an individual's risk of developing high blood pressure based on detection of inherited gene variations that encode for a protein called G protein coupled receptor kinase type 4 (GRK4). GRK4 variations are associated with an inability to normally eliminate sodium from the body.

"Patients with even a single GRK4 variation have a significant lifetime risk for developing hypertension," said Pedro A. Jose, MD, PhD, professor of pediatrics and of physiology and biophysics at Georgetown, the senior author of the PNAS paper. "We have now identified the genetic abnormalities that cause this error and so we have a better idea of the impact of these gene variations in the development of hypertension in three distinct racial groups."

"This discovery has led to a high quality test that should be suitable for screening a large number of patients based on a fluorescent molecular beacon assay and will aid physicians in their diagnosis of genetic forms of hypertension," said Robin A. Felder, Ph.D., professor of pathology and director of the Medical Automation Research Center of the University of Virginia, the lead author on the paper. "The genetic information disclosed by the test will allow physicians to provide guidance to patients with a family history of hypertension who wish to know if they should modify their lifestyles to help prevent the debilitating consequences such as kidney failure, heart failure, stroke, blindness of high blood pressure," said Dr. Jose and Dr. Felder.

Identification of this leading cause of hypertension should lead to improved medical treatments for the disease. The University of Virginia and Georgetown teams, in collaboration with Dr. Hironobu Sanada at Fukushima University in Japan, have also reported on the use of antisense technology to correct the biochemical error in human kidney cells that leads to the high blood pressure. The research teams have produced human kidney cell lines that may be useful in discovering other therapeutic methods to treat high blood pressure.
-end-
Dr. Felder and Dr. Jose submitted their discoveries for patent protection in January 1999. The resulting patents have been recently assigned to Hypogen Inc. in Charlottesville, Va. The research reported in PNAS was funded by the National Institutes of Health (National Heart Lung and Blood Institute, National Institute for Diabetes, Digestive, and Kidney Diseases and the National Center for Research Resources).

Georgetown University Medical Center includes the nationally ranked School of Medicine, School of Nursing and Health Studies, the Lombardi Cancer Center and a biomedical research enterprise. For more information, visit www.georgetown.edu/gumc.

Georgetown University Medical Center

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.